ABCELLERA BIOLOGICS - Asset Resilience Ratio

Latest as of December 2025: 29.87%

ABCELLERA BIOLOGICS (8QQ) has an Asset Resilience Ratio of 29.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 8QQ PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€405.31 Million

≈ $473.85 Million USD Cash + Short-term Investments

Total Assets

€1.36 Billion

≈ $1.59 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ABCELLERA BIOLOGICS's Asset Resilience Ratio has changed over time. See ABCELLERA BIOLOGICS balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down ABCELLERA BIOLOGICS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABCELLERA BIOLOGICS stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€405.31 Million	29.87%
Total Liquid Assets	€405.31 Million	29.87%

Asset Resilience Insights

Very High Liquidity: ABCELLERA BIOLOGICS maintains exceptional liquid asset reserves at 29.87% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

ABCELLERA BIOLOGICS Industry Peers by Asset Resilience Ratio

Compare ABCELLERA BIOLOGICS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
BB Biotech AG SW:BION	Biotechnology	0.05%
Concord Biotech Limited NSE:CONCORDBIO	Biotechnology	18.00%
Pharming Group NV AS:PHARM	Biotechnology	7.13%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	Biotechnology	56.48%

Annual Asset Resilience Ratio for ABCELLERA BIOLOGICS (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ABCELLERA BIOLOGICS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	29.87%	€405.31 Million ≈ $473.85 Million	€1.36 Billion ≈ $1.59 Billion	-4.62pp
2024-12-31	34.49%	€469.29 Million ≈ $548.65 Million	€1.36 Billion ≈ $1.59 Billion	-7.66pp
2023-12-31	42.15%	€627.26 Million ≈ $733.34 Million	€1.49 Billion ≈ $1.74 Billion	+9.71pp
2022-12-31	32.45%	€499.95 Million ≈ $584.49 Million	€1.54 Billion ≈ $1.80 Billion	+13.73pp
2021-12-31	18.72%	€246.84 Million ≈ $288.58 Million	€1.32 Billion ≈ $1.54 Billion	--

pp = percentage points

About ABCELLERA BIOLOGICS

F:8QQ Germany Biotechnology

Market Cap

$1.70 Billion

€1.45 Billion EUR

Market Cap Rank

#8036 Global

#1061 in Germany

Share Price

€4.76

Change (1 day)

-8.73%

52-Week Range

€2.49 - €5.60

All Time High

€44.98